EMA Recommends Granting a Marketing Authorisation for Camizestrant By Ogkologos - June 5, 2026 80 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of patients with ER-positive, HER2-negative advanced breast cancer with ESR1 mutations Source RELATED ARTICLESMORE FROM AUTHOR Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma FDA Approves Durvalumab in Combination with BCG for High-Risk Non-Muscle Invasive Bladder Cancer Systemic Aging Associated with a Higher Risk of Early-Onset Solid Cancers MOST POPULAR Efficacy and Safety of Entrectinib in Advanced ROS1 Fusion–Positive Non–Small Cell... March 15, 2021 Larger NGS Gene Panel Linked to More Clinical Utility October 16, 2020 Pan-FGFR Tyrosine Kinase Inhibitor Treatment Is Less Effective in Patients with... March 2, 2021 Pralsetinib: Measures to Minimise Increased Risk for Tuberculosis May 25, 2023 Load more HOT NEWS Gynaecological Cancers: Immunotherapy and Novel Targeted Drug Appear Beneficial in Group... Pembrolizumab Improves Survival in Patients from Asia with Previously Treated Advanced... Dog Finds Woman’s Lost Wedding Ring At The Beach FDA Approves Second CAR T-Cell Therapy for Lymphoma
